Preoperative Capecitabine/RT Downstages Rectal Cancer

Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

TAEJON, Korea-In a study from Korea of patients with locally advanced rectal cancer, preoperative capecitabine (Xeloda) with leucovorin given concurrently with radiotherapy resulted in primary tumor downstaging and nodal downstaging, reported Jun-Sang Kim, MD, of Chungnam National University, Taejon, and colleagues.

TAEJON, Korea—In a study from Korea of patients with locally advanced rectal cancer, preoperative capecitabine (Xeloda) with leucovorin given concurrently with radiotherapy resulted in primary tumor downstaging and nodal downstaging, reported Jun-Sang Kim, MD, of Chungnam National University, Taejon, and colleagues.

In a separate study, German scientists evaluating concurrent capecitabine/radiotherapy in rectal cancer found the approach feasible and well tolerated with promising preliminary efficacy results.

Both researchers noted that oral chemotherapy with capecitabine mimics the pharmacokinetics of continuous fluoro-uracil (5-FU) infusion as a radiation sensitizer. Continuous infusion 5-FU has been shown to cause tumor downstaging when given preoperatively in locally advanced rectal cancer patients and to improve resectability.

The Korean study enrolled 45 patients. The whole pelvis radiotherapy dose was 45 Gy given in 25 fractions over 5 weeks, followed by a boost dose of 5.4 Gy in three fractions to the primary tumor. Chemotherapy, administered concurrently, consisted of two 14-day cycles of capecitabine 825 mg/m2 twice daily and leucovorin 10 mg/m2 twice daily. Each cycle was followed by a 7-day rest period. Surgery was performed 6 weeks after the completion of chemoradiation.

Of 38 patients who underwent definitive surgery, primary tumor downstaging occurred in 63% and nodal downstaging in 90%, for an overall downstaging rate of 84%. The pathologic complete response rate was 31%.

Among 21 patients with distal tumors (located initially 5 cm or less from the anal verge), 18 underwent surgery. Of these, 13 (72%) received sphincter-preserving surgery (Int J Radiation Oncology Biol Phys 34:403-408, 2002).

Grade 3 toxicities included hand-foot syndrome (7%), fatigue (4%), diarrhea (4%), and radiation dermatitis (2%). There were no grade 3-4 hematologic toxicities.

The researchers concluded that although longer follow-up is necessary, "these preliminary results suggest that preoperative chemoradiation with capeci-tabine is a safe, well-tolerated, and effective neoadjuvant treatment modality for locally advanced rectal cancer." The downstaging effect, they said, "can increase the possibility of sphincter preservation in distal rectal cancer."

German Study

German researchers conducted a phase I, dose-escalation study to determine the maximum tolerated dose of oral capecitabine given concurrently with standard pelvic radiotherapy in patients with rectal cancer treated in the adjuvant, neoadjuvant, or palliative setting. "In order to optimally exploit any potential synergistic effect of radiotherapy and capecitabine, the drug was planned to be administered continuously for the duration of irradiation," said Jürgen Dunst, MD, of Martin-Luther-Universi-tät, Halle, Germany, and his colleagues.

Radiotherapy was given to a total dose of 50.4 Gy in 1.8-Gy daily fractions, 5 days a week for approximately 6 weeks. The planned capecitabine dose escalation was from 250 to 1,250 mg/m2 twice daily, including weekends, with the first dose given approximately 2 hours before radiotherapy and the second dose 12 hours after the first.

The study recruited 36 patients, 92% of whom had newly diagnosed rectal cancer and the remainder relapsed disease. There were no dose-limiting toxicities up to the 825 mg/m2 twice daily dose level. At 1,000 mg/m2 twice daily, two patients had grade 3 hand-foot syndrome. Consequently, 825 mg/m2 twice daily is the recommended dosage for subsequent trials (J Clin Oncol 20:3983-3991, 2002).

Of 10 patients treated in the neoadju-vant setting for whom effects on the primary tumor could be assessed, 9 had a clinical partial response and one had stable disease. One patient treated at the 500 mg/m2 twice daily dose level had a histologic complete remission. Of three patients with relapsed disease treated palliatively, one had a partial remission at a dose level of 825 mg/m2 twice daily.

In this study, the acute side effects of radiotherapy, especially bowel and skin toxicity in the radiation field, "were not increased and were not dose limiting," the authors said, whereas bowel toxicity is the main toxicity of radiotherapy and concurrent standard 5-FU.

The authors noted that a multicenter phase II study has begun in Germany using the recommended capecitabine dose to evaluate concurrent capecitabine/radiotherapy in the neoadjuvant setting. Further, the treatment schedule developed in this phase I trial has been adopted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) for a planned large-scale trial in the preoperative setting of capecitabine/radiotherapy vs protracted 5-FU/radiotherapy. 

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content